175 related articles for article (PubMed ID: 27491040)
1. Akt mediates TIGAR induction in HeLa cells following PFKFB3 inhibition.
Simon-Molas H; Calvo-Vidal MN; Castaño E; Rodríguez-García A; Navarro-Sabaté À; Bartrons R; Manzano A
FEBS Lett; 2016 Sep; 590(17):2915-26. PubMed ID: 27491040
[TBL] [Abstract][Full Text] [Related]
2. TP53-inducible Glycolysis and Apoptosis Regulator (TIGAR) Metabolically Reprograms Carcinoma and Stromal Cells in Breast Cancer.
Ko YH; Domingo-Vidal M; Roche M; Lin Z; Whitaker-Menezes D; Seifert E; Capparelli C; Tuluc M; Birbe RC; Tassone P; Curry JM; Navarro-Sabaté À; Manzano A; Bartrons R; Caro J; Martinez-Outschoorn U
J Biol Chem; 2016 Dec; 291(51):26291-26303. PubMed ID: 27803158
[TBL] [Abstract][Full Text] [Related]
3. Sirtuin 3 Alleviates Diabetic Cardiomyopathy by Regulating TIGAR and Cardiomyocyte Metabolism.
Li L; Zeng H; He X; Chen JX
J Am Heart Assoc; 2021 Feb; 10(5):e018913. PubMed ID: 33586458
[TBL] [Abstract][Full Text] [Related]
4. Phosphorylation of the 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatase/PFKFB3 family of glycolytic regulators in human cancer.
Bando H; Atsumi T; Nishio T; Niwa H; Mishima S; Shimizu C; Yoshioka N; Bucala R; Koike T
Clin Cancer Res; 2005 Aug; 11(16):5784-92. PubMed ID: 16115917
[TBL] [Abstract][Full Text] [Related]
5. PFKFB3 activation in cancer cells by the p38/MK2 pathway in response to stress stimuli.
Novellasdemunt L; Bultot L; Manzano A; Ventura F; Rosa JL; Vertommen D; Rider MH; Navarro-Sabate À; Bartrons R
Biochem J; 2013 Jun; 452(3):531-43. PubMed ID: 23548149
[TBL] [Abstract][Full Text] [Related]
6. TGF-β1 targets Smad, p38 MAPK, and PI3K/Akt signaling pathways to induce PFKFB3 gene expression and glycolysis in glioblastoma cells.
Rodríguez-García A; Samsó P; Fontova P; Simon-Molas H; Manzano A; Castaño E; Rosa JL; Martinez-Outshoorn U; Ventura F; Navarro-Sabaté À; Bartrons R
FEBS J; 2017 Oct; 284(20):3437-3454. PubMed ID: 28834297
[TBL] [Abstract][Full Text] [Related]
7. TIGAR cooperated with glycolysis to inhibit the apoptosis of leukemia cells and associated with poor prognosis in patients with cytogenetically normal acute myeloid leukemia.
Qian S; Li J; Hong M; Zhu Y; Zhao H; Xie Y; Huang J; Lian Y; Li Y; Wang S; Mao J; Chen Y
J Hematol Oncol; 2016 Nov; 9(1):128. PubMed ID: 27884166
[TBL] [Abstract][Full Text] [Related]
8. Nuclear targeting of 6-phosphofructo-2-kinase (PFKFB3) increases proliferation via cyclin-dependent kinases.
Yalcin A; Clem BF; Simmons A; Lane A; Nelson K; Clem AL; Brock E; Siow D; Wattenberg B; Telang S; Chesney J
J Biol Chem; 2009 Sep; 284(36):24223-32. PubMed ID: 19473963
[TBL] [Abstract][Full Text] [Related]
9. Role of Akt/PKB and PFKFB isoenzymes in the control of glycolysis, cell proliferation and protein synthesis in mitogen-stimulated thymocytes.
Houddane A; Bultot L; Novellasdemunt L; Johanns M; Gueuning MA; Vertommen D; Coulie PG; Bartrons R; Hue L; Rider MH
Cell Signal; 2017 Jun; 34():23-37. PubMed ID: 28235572
[TBL] [Abstract][Full Text] [Related]
10. TIGAR, a p53-inducible regulator of glycolysis and apoptosis.
Bensaad K; Tsuruta A; Selak MA; Vidal MN; Nakano K; Bartrons R; Gottlieb E; Vousden KH
Cell; 2006 Jul; 126(1):107-20. PubMed ID: 16839880
[TBL] [Abstract][Full Text] [Related]
11. 6-Phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 and 4: A pair of valves for fine-tuning of glucose metabolism in human cancer.
Yi M; Ban Y; Tan Y; Xiong W; Li G; Xiang B
Mol Metab; 2019 Feb; 20():1-13. PubMed ID: 30553771
[TBL] [Abstract][Full Text] [Related]
12. 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase and tumor cell glycolysis.
Chesney J
Curr Opin Clin Nutr Metab Care; 2006 Sep; 9(5):535-9. PubMed ID: 16912547
[TBL] [Abstract][Full Text] [Related]
13. PFKFB3 blockade inhibits hepatocellular carcinoma growth by impairing DNA repair through AKT.
Shi WK; Zhu XD; Wang CH; Zhang YY; Cai H; Li XL; Cao MQ; Zhang SZ; Li KS; Sun HC
Cell Death Dis; 2018 Apr; 9(4):428. PubMed ID: 29559632
[TBL] [Abstract][Full Text] [Related]
14. PFKFB3 modulates glycolytic metabolism and alleviates endoplasmic reticulum stress in human osteoarthritis cartilage.
Qu J; Lu D; Guo H; Miao W; Wu G; Zhou M
Clin Exp Pharmacol Physiol; 2016 Mar; 43(3):312-8. PubMed ID: 26718307
[TBL] [Abstract][Full Text] [Related]
15. Small molecule inhibition of 6-phosphofructo-2-kinase suppresses t cell activation.
Telang S; Clem BF; Klarer AC; Clem AL; Trent JO; Bucala R; Chesney J
J Transl Med; 2012 May; 10():95. PubMed ID: 22591674
[TBL] [Abstract][Full Text] [Related]
16. Regulatory role of TIGAR on endothelial metabolism and angiogenesis.
He X; Zeng H; Cantrell AC; Chen JX
J Cell Physiol; 2021 Nov; 236(11):7578-7590. PubMed ID: 33928637
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of 6-phosphofructo-2-kinase (PFKFB3) suppresses glucose metabolism and the growth of HER2+ breast cancer.
O'Neal J; Clem A; Reynolds L; Dougherty S; Imbert-Fernandez Y; Telang S; Chesney J; Clem BF
Breast Cancer Res Treat; 2016 Nov; 160(1):29-40. PubMed ID: 27613609
[TBL] [Abstract][Full Text] [Related]
18. Targeting MUC1-C inhibits the AKT-S6K1-elF4A pathway regulating TIGAR translation in colorectal cancer.
Ahmad R; Alam M; Hasegawa M; Uchida Y; Al-Obaid O; Kharbanda S; Kufe D
Mol Cancer; 2017 Feb; 16(1):33. PubMed ID: 28153010
[TBL] [Abstract][Full Text] [Related]
19. PFKFB3-mediated glycolysis is involved in reactive astrocyte proliferation after oxygen-glucose deprivation/reperfusion and is regulated by Cdh1.
Lv Y; Zhang B; Zhai C; Qiu J; Zhang Y; Yao W; Zhang C
Neurochem Int; 2015 Dec; 91():26-33. PubMed ID: 26498254
[TBL] [Abstract][Full Text] [Related]
20. The potential utility of PFKFB3 as a therapeutic target.
Bartrons R; Rodríguez-García A; Simon-Molas H; Castaño E; Manzano A; Navarro-Sabaté À
Expert Opin Ther Targets; 2018 Aug; 22(8):659-674. PubMed ID: 29985086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
